Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

Authors:

Abstract
Identification of tumor genomic alterations predictive of therapeutic benefit from targeted therapy has improved clinical outcomes across a wide range of malignant neoplasms.1-7 Examples include EGFR-mutant non–small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors, ERBB2 (formerly HER2/neu)-amplified breast cancer treated with human epidermal growth factor receptor 2–specific antibodies, and tumors with microsatellite instability treated with immune checkpoint blockade. Because identification of these targets susceptible to drug therapy has improved clinical outcomes, interest in using next-generation sequencing (NGS) testing for advanced solid tumors to identify patients who qualify for enrollment in biomarker-selected clinical trials is increasing. Next-generation sequencing testing can be obtained via commercial or institutional platforms, and these differ significantly in their scope; some are limited to DNA-based testing of a select group of known, targetable cancer-related genes. Others use unbiased, comprehensive DNA- and RNA-based analyses of samples consisting of tumor and normal samples, with additional goals of identifying novel somatic alterations or pathogenic germline variants (PGVs) conferring increased cancer risk.

This publication has 35 references indexed in Scilit: